Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE (PAR: OSE) presents full CoTikiS results at ECCO 2025
Published by Arron Aatkar, PhD

OSE Immunotherapeutics reported the full induction results from the CoTikiS trial at ECCO 2025 (the 20th congress of the European Crohn’s and Colitis Organisation), as part of the top 10 congress highlights oral plenary session. CoTikiS was a randomised, double-blind, Phase II study assessing the company’s IL-7R monoclonal antibody (mAb) therapy in patients with moderate to severe ulcerative colitis (UC). At ECCO, OSE also presented encouraging preclinical data on the combination of anti-IL-7 receptor with anti-IL-12/23 mAb in chronic colitis.

See here for details on the upcoming webinar: Lusvertikimab and the future of IBD: KOL insights post-ECCO.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.